Your session is about to expire
← Back to Search
TATE + Pembrolizumab for Lung Cancer
Study Summary
This trial is testing a new cancer treatment involving Trans-arterial Tirapazamine Embolization (a minimally-invasive procedure) and Pembrolizumab (a cancer immunotherapy drug). The trial is for patients with metastatic non-small cell lung cancer that has spread to the liver, and who have not responded to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had major stomach or intestinal bleeding in the last 2 months.I am fully active or can carry out light work.My cancer has spread to the liver and does not have EGFR or AKT mutations.My cancer has spread to my brain.My organs are working well.My colorectal cancer has worsened after two treatments, or my lung cancer has worsened after chemotherapy and immunotherapy.I have had an organ transplant.It's been over 4 weeks since my last chemotherapy and I don't have side effects.The disease can be measured or seen on tests.Over half of my liver is affected by cancer.
- Group 1: NSCLC
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the overarching objective of this experiment?
"For the next two years, this medical trial will be monitoring primary outcome of Overall Response Rate (ORR) among patients with NSCLC. Additionally, they are tracking secondary outcomes such as Overall Survival (OS), Progression Free Survival (PFS), and Duration of Response according to RECIST 1.1 guidelines."
How many individuals are selected for participation in this research project?
"Affirmative. The information hosted on clinicaltrials.gov reveals that this experiment, which was initially made public on May 20th 2021, is presently seeking participants. A total of 110 volunteers are required to be recruited from a single medical facility."
What other scientific investigations have been conducted to explore the effects of TATE and pembrolizumab?
"At present, 961 clinical studies are running examining the effectiveness of TATE and pembrolizumab. Of those trials, 122 have advanced to Phase 3. The bulk of these experiments take place in Houston, Texas; however there are 35731 different medical sites running tests with this treatment worldwide."
To what conditions have TATE and pembrolizumab been effectively deployed?
"TATE and pembrolizumab is a therapeutic intervention frequently used to combat malignant neoplasms, although it can also be employed in cases of unresectable melanoma, microsatellite instability high, or post-chemotherapy disease progression."
Is the process of enrolling in this trial open at present?
"Correct. Clinicaltrials.gov contains data that confirms the recruitment period of this clinical trial, which began on May 20th 2021 and was last updated April 13th 2022 is still active. One location is needed to meet the goal of enrolling 110 patients in total."
Is the concurrent use of TATE and pembrolizumab considered to be a safe therapeutic approach?
"Our internal assessment gauged the safety of TATE and pembrolizumab as a 2, due to Phase 2 trial results that demonstrate some security but no evidence for efficacy."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger